1.

Introduction
Several large trials have demonstrated the efficacy of statins in the primary prevention of cardiovascular events, including first acute major coronary event in adults with average triglycerides (TG) and low-density lipoprotein-cholesterol (LDL-C) and below average high-density lipoprotein-cholesterol (HDL-C) levels. [1] [2] [3] [4] Further, trials on statin therapy such as Scandinavian Simvastatin Survival Study (4S) 5 and Cholesterol and Recurrent Events Trial (CARE) 6 also established their role in reducing coronary events such as stroke risk, fatal coronary artery disease (CAD) and nonfatal myocardial infarction (MI). For secondary prevention of acute coronary events, high levels of LDL-C, carotid artery remodeling, morbid obesity and low levels of HDL-C are important prognostic indicators to evaluate the efficacy of aggressive lipid therapy strategies. 7 The prevalence of dyslipidemia is increased in diabetic patients, which contributes to the higher incidence of cardiovascular diseases (CVDs), resulting in higher morbidity and mortality. 8 The American Diabetes Association recommends the use of statins by diabetic patients with overt CVD and by patients without CVD who are older than 40 years of age and have one or more CVD risk factors, regardless of baseline lipid levels. 9 At present, statins are the gold-standard treatment options for lowering LDL-C. Additionally statins are also known for their ability to reduce the risk of cardiovascular events and their excellent safety profile. [10] [11] [12] Besides LDL-C, other lipid parameters, such as high TG 13, 14 and low HDL-C levels 15, 16 also play a role in the causation and progression of coronary heart disease (CHD). One of the Cholesterol Treatment Trialists' Collaboration (CCT) meta-analyses states that statin therapy can safely reduce the 5-year incidence of major coronary events, coronary revascularization, and stroke by about one fifth per mmol/L reduction in LDL cholesterol, largely irrespective of the initial lipid profile or other presenting characteristics. 17 Management of lipid parameters beyond LDL-C may require additional therapeutic or non-therapeutic options to statin therapy, to likely benefit the patients with residual risks. 18, 19 In clinical practice, there is scarce information about the extent to which CHD patients on lipid therapy achieve control of HDL-C, LDL-C, and TG. Further, there is paucity of data regarding occurrence of cardiovascular events among patients with mixed dyslipidemia (at least 2 lipid abnormalities) compared to patients with LDL-C abnormalities alone. There is also a lack of understanding in the use of comprehensive lipid management therapies to target dyslipidemia beyond LDL-C as a secondary prevention measure subsequent to a CHD event.
In India, there is a wide gap in translation of evidence to practice. Though there is evidence 20 to suggest that in patients with diabetes, low HDL-C levels are stronger predictor of mortality from CHD than LDL-C, further quantification of protocol based treatment regimen as well as residual abnormality and risk has never been studied. The primary objective of our observational study was to evaluate the effect of statin therapy/LLT on lipid profile, in Indian adults presenting with first acute coronary event. The prevalence of mixed dyslipidemia, the need to address low HDL-C and/or high TG in addition to, or in the absence of high LDL-C post statin therapy/LLT, and the various risk subgroups (including individuals with prevalent diabetes mellitus) were also assessed.
2.
Materials and methods
Study design
We conducted a multicenter, observational, prospective cohort study in 19 tertiary care centers of India in patients with first acute coronary event. The study was planned for 12 weeks from the onset of first acute coronary event. However, all patients who were on statin therapy/LLT (as per the discretion of their respective investigators) for an average of 13.5 weeks were analyzed in this study. This was taken as the end of study (EOS) period.
Setting
The study was initiated on 23rd April 2010 and was completed at all the centers by 15th December 2012. The patients were enrolled at the time of their first acute coronary event presentation (Index Date), information about demographics; current medical treatment, family history and acute coronary event were collected by interviewing the patients. Physical examination was conducted of all the patients prior to discharge. At baseline and EOS visits, investigations and lipid assessments were performed. The study flow chart is presented in Fig. 1 . The required study data was collected and entered into a case record form (CRF 
Treatment
There was no protocol specified treatment or intervention that was given to the patient, however as per the eligibility, the trial patients were considered for initiation/maintenance/modification of statin therapy before discharge from hospital. Statin therapies prescribed in all the trial sites as per the institutional regimen included atorvastatin (10, 20, 40 , 80 mg), rosuvastatin (10, 20 and 40 mg), simvastatin (40 mg) and other LLT, such as fenofibric acid/fenofibrate (145 and 160 mg).
End-points
The primary end-points described the lipid profile and quantified the inadequacy/under treatment with statins among all patients and various risk subgroups (including individuals with prevalent diabetes mellitus) experiencing their first acute coronary event. The secondary end-points were the prevalence of mixed dyslipidemia and the need to address low HDL-C and/or high TG in addition to, or in the absence of high LDL-C, at EOS, post statin therapy/LLT subsequent to the first acute coronary event among all patients, as well as to assess the risk subgroups (including individuals with prevalent diabetes mellitus).
Statistical methods
The study was not based on a hypothesized effect size; hence, a formal estimation of statistical power was not applicable. All statistical analyses were performed using SAS ® for Windows ). Blood pressure was measured minimum of 2 times and an average of SBP and DBP was used; if measured more than twice. Multiple logistic analyses were used to obtain association between risk factors and for sub-group analysis in diabetic and non-diabetic patients. Descriptive statistics of observed values and changes from baseline were provided for all above vital signs and laboratory parameters. No formal inferential statistical analysis was performed for these parameters.
Results
A total of 635 patients were enrolled in the study, of which 514 (80.9%) had completed data. Of these 514 patients with completed data, 40 (6.3%) patients discontinued from the study. Four hundred and seventy four (74.6%) patients completed the study and were included in the FAS dataset. All the 635 enrolled patients were included in the SAF dataset. A summary of patient's demographic characteristics is as shown in Table 1 . The mean (SD) age of the patients was 54.2 (10.60) years and the mean (SD) BMI (kg/m 2 ) was 25.56 (3.649). Of 474 patients who completed the study, 80.2% were male patients (n = 380) whereas female patients comprising only 19.8% (n = 94), with majority of female patients being in postmenopausal phase (83/94 [88.3%]). Among the completers, 195 (41.1%) patients had history of hypertension and 137 (28.9%) patients had history of diabetes mellitus. At baseline, 453 (95.6%) patients were not on statin therapy and only 21 (4.4%) patients were taking statins, for a median duration of one week, at the time of enrolment (there was an outlier, one subject who was on statin therapy since 381 weeks). All the patients at baseline (n = 635) as well as at EOS (n = 474) i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) 6 4 6 -6 5 4 belonged to the National Cholesterol Education ProgramAdult Treatment Panel III (NCEP ATP III) high risk group. The details of prevalence of dyslipidemia at baseline and at EOS are presented in Table 2 . The number of patients with LDL-C (all) abnormality decreased from 24.9% (n = 118) at visit 1 to 5.7% (n = 27) at EOS. Similar trend was also seen in patients with LDL-C (only) abnormality wherein the values decreased from 9.7% (n = 46) at baseline to 2.7% (n = 13) at EOS. However, an inverse trend was observed in the number of patients with HDL fraction abnormality, namely HDL-C (all), HDL-C (only), i . Hence, majority of the patients were non-smokers and did not consume alcohol. A total of 273 (57.6%) patients had at least one medical history at baseline.
There were a total of 45 (9.5%) patients with at least one family history, of which 28 (5.9%) had family history of diabetes and 22 (4.6%) had family history of MI or sudden death either before the age of 55 years for males, or 65 years for females. A summary of lipid lowering agents by dose is provided in Table 3 . Atorvastatin 40 mg had been prescribed to a majority of patients during hospitalization (n = 235). The same trend was also seen at EOS i.e. at week 12 (n = 242), followed by Atorvastatin 80 mg which was prescribed to 157 patients at visit 1 and 146 patients at EOS, and Atorvastatin 20 mg had been prescribed to 49 patients at visit 1 and 73 patients at EOS. Rosuvastatin (10 mg, 20 mg and 40 mg), simvastatin 40 mg and fenofibric acid (145 and 160 mg) was prescribed to a very small number of patients.
A table of multivariate analysis presenting association between dyslipidemia, statin therapy/LLT and patient characteristics is provided in Table 4 . Elevated LDL-C and TG, and low HDL-C had statistically significant associations (p < 0.05) with patient characteristics such as age, diabetes, cigarette smoking, BMI, gender, and hypertension at baseline, and with hypertension and age at EOS. The subgroup analysis of 137 diabetic patients and 336 non-diabetic patients presenting association between dyslipidemia, statin therapy/LLT and patient characteristics are as shown in Table 5 . In diabetic patients, low HDL-C and elevated TG had statistically significant associations (p < 0.05) with cigarette smoking, BMI, gender at baseline, and with cigarette smoking and hypertension at EOS, for elevated TG. In non-diabetic patients, elevated LDL-C, low HDL-C and elevated TG had statistically significant associations (p ≤ 0.05) with age, cigarette smoking, BMI, gender, and hypertension at baseline, and with age at EOS, for low LDL-C and elevated TG. The median change from baseline to visit 2 (EOS) was À35 in TC (mg/dl), À33 in measured LDL-C (mg/dl), À1 in HDL-C (mg/dl), 3 in TG (mg/dl), 4 in lipoprotein (a) (NMOL/L), 7 in apoprotein A1 (mg/dl), À7.55 in hs-CRP (mg/L), and no change in HbA1c (%). The median change from baseline to visit 2 values suggests improvement in the laboratory values of TC, LDL-C and hs-CRP. However, there was marginal to no change or deterioration observed at EOS in the values of HDL-C, TG, lipoprotein (a), apoprotein A1 and HbA1c. Serious adverse events (SAEs) by system organ class (SOC) and preferred term (PT) are presented in Table 6 . Of 474 patients, 6 (1.3%) patients had a total of seven SAEs. Of the seven SAEs by SOC, 5 (1.1%) belonged to cardiac disorders, 1 (0.2%) to infections and infestations, and 1 (0.2%) to nervous system disorder. No major change from baseline to EOS was observed in any of the median values of the vital signs. The physical examination findings were similar for all the parameters for both baseline and EOS visits. All the patients in SAF had at least one clinical information data, however, none had occurrence of any major event during the follow-up period. All the patients (474) had taken statin therapy/LLT during the follow-up and had taken other concomitant medication at discharge.
Discussion
In the current observational study, statin therapy/LLT was found to be effective in reducing the number of patients with primarily abnormal LDL-C fraction and mixed dyslipidemia. Our findings are consistent with the Prospective Cardiovascular Münster (PROCAM, 2010) study, which showed that many MI survivors had high TG and/or low HDL-C versus matched controls, and CV risk associated with the dyslipidemic profile was higher despite low LDL-C levels. 21 High LDL-C had statistically significant association with age ( p = 0.0078), Percentages are based on number of patients in full analysis set (FAS). a One patient has been counted at more than one instance in statin or other.
i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) 6 4 6 -6 5 4 diabetes (p = 0.0002), cigarette smoking (p = 0.0049) at baseline. The association of high LDL-C with age, diabetes, cigarette smoking, and hypertension highlights the importance of treating abnormal LDL-C levels in patients with such risk factors. In diabetic patients the LDL-C levels increased with hypertension. The LDL-C levels also increased with prior cerebro-vascular disease. In non-diabetic patients, the association of high LDL-C was statistically significant with age, hypertension and cigarette smoking prior to statin therapy but the association was not statistically significant post statin therapy. Our findings are similar to a period prevalence study in which it was observed that co-occurrence of diabetes mellitus, hypertension, and high LDL-C mandates comprehensive disease management strategies. 22 The EUROASPIRE IV study reported that only one-fifth of the patients on lipidlowering medication achieved the Joint European Societies (JES) 2012 CVD prevention guidelines recommended LDL-C lowering target of ≤1.8 mmol/L. The study concluded that coronary patients require more intensive cholesterol management. 23 However, in non-diabetic patients, low HDL-C had no statistical significant association with BMI and gender (male over female); and this association either remained unchanged or decreased post statin therapy. High TG had statistically significant association (p < 0.05) with BMI ( p = 0.0091), hypertension (p = 0.0148), and cigarette smoking (p = 0.0049) prior to statin therapy. In diabetic patients, TG levels increased with cigarette smoking and gender (male over female) both pre and post statin therapy; marginally increased with BMI prior to statin therapy and post statin therapy it either remained unchanged or decrease. However, in non-diabetic patients, high TG levels had statistically significant association with hypertension prior to therapy and no significant association with cigarette smoking. Post therapy the association either remained unchanged or decreased. The findings of HDL-C and TG abnormalities are similar to those of the Copenhagen male study, which stated that high TG-low HDL-C were powerful predictors of IHD besides isolated high LDL-C. That study inferred that prevention of IHD should emphasize on interventions targeting at high TG-low HDL-C and not just manage overall hypercholesterolemia. 24 A study of 1800 adults in India revealed a high incidence of dyslipidemia; the prevalence being higher in males. 25 It was found that high cholesterol and high TG were more prominent in adults aged 31-40 years than those under age 30. Another study investigating dyslipidemia in Asian Indians residing in India showed that the overall prevalence of dyslipidemia ranged from 10% to 73%. Specifically, prevalence of hypercholesterolemia was 28% in urban patients as compared to 22% in the rural patients. 26 High TG, low HDL-C and high LDL-C levels characterize typical lipid profile in the Indian population. Our findings signify the need to treat high LDL-C as well as low HDL-C and high TG in diabetic population with associated risk factors such as hypertension, BMI and gender (male over female). Published literature has also reported that lipid abnormalities (high LDL-C, low HDL-C and high TG) frequently accompany both hypertension and glucose intolerance in diabetes and in the metabolic syndrome. 27, 28 Inclusion of other drugs in addition to statin therapy was suggested by Cziraky et al. to promote the cost-effective i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) 6 4 6 -6 5 4 i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) 6 4 6 -6 5 4
achievement of optimum lipid levels in several at-risk patients. 18 A similar study conducted in France 29 demonstrated that a significant proportion of dyslipidemic patients at high CV risk did not achieve treatment goals even after statin therapy. Though statin therapy alone is not sufficient for managing lipid parameters, a study by Larsen et al. emphasized the need of statin therapy to prevent adverse clinical events, major adverse cardiac events, major bleeding unrelated to bypass surgery, and death. Absence of a discharge statin prescription after STEMI was an independent predictor of ischemic events including death in this study. 30 In daily clinical practice, almost one-third of patients with a history of coronary event have residual lipid risk including LDL-C <100 mg/dl, low HDL-C and/or high TG, known as residual lipid risk. 31 Though statin therapy is effective, a substantial proportion of patients still remain with residual dyslipidemia. Several large studies (CEPHEUS, DYSIS) have reported the need for comprehensive and intensive surveillance, awareness and treatment regimen for lowering lipids, especially in patients at a high risk for CVD. 32, 33 This observational cohort study had a few inherent limitations. The study design itself could be associated with introduction of bias at different stages. The other biases were sampling and effect size, which were not taken into consideration. Also, observation was not restricted to statin therapy alone, but other LLT were also observed and assessed.
Conclusion
In conclusion, management of lipid parameters beyond LDL-C would require additional therapeutic and non-therapeutic options to statin therapy/LLT, to likely benefit the patients with residual risks. The scope of comprehensive lipid management therapies may also include reducing the residual cardiovascular risks associated with low HDL-C levels and high TG levels. Future research directed toward comprehensive drug therapy regimen for the management of overall lipid abnormalities, in primary and secondary prevention of cardiovascular events is suggested.
Key messages:
(1) In our study, statin therapy/LLT was found to be effective in reducing the number of patients with primarily abnormal LDL-C fraction and mixed dyslipidemia. But statin therapy/LLT was not effective in managing HDL fraction, lipoprotein (a) and TG abnormalities. (2) Management of lipid parameters beyond LDL-C would require additional therapeutic and non-therapeutic options to statin therapy/LLT, to likely benefit the patients with residual risks.
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